Lowering Medicare & Medicaid pharmaceutical spend with advanced cost containment systems; Lowering Medicare & Medicaid pharmaceutical spend with advanced cost containment systems
Government Entities
Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
IDs
Filing UUID:39035232-7f0b-487d-88f7-f1fdf94f146f
Registrant ID:400786367
Client ID:64818
2026-04-01
CORNERSTONE GOVERNMENT AFFAIRS, INC.
EMPOWER CLINIC SERVICES, LLC DBD EMPOWER PHARMACY
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Issues related to physician and pharmacy organization coalitions, regulatory reforms affecting pharmaceutical compounding, patient access, and domestic drug supply resilience.
IDs
Filing UUID:e4f9b178-4f27-41df-a5f1-28602cd27cf8
Registrant ID:75557
Client ID:72121
2026-04-01
ELITE STRATEGIC SERVICES
CONSERVATIVES FOR PROPERTY RIGHTS
$25,000
$0
Filing Details
Type: ld2 • Year: 2026 Q1
Specific Issues
CPT: Senate, House, Department of Commerce, Patent & Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, White House Executive Office of the President, Office of Science and Technology Policy S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498, as requested by Knowledge Ecology International (KEI) of the Department of Health and Human Services (HHS), as drug price controls to expropriate pharma patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution Proposed violation of the Bayh-Dole Act by the government taking a share of the patent licensing royalties of universities patented inventions United Kingdom (UK) Intellectual Property Office (IPO) proposal of a government-run licensing fee-setting scheme for standard-essential patents U.S. Patent and Trademark Office Notice of Proposed Rulemaking (NPRM) to improve the Patent Trial and Appeal Boards (PTAB) practices for instituting inter partes review (IPR) challenges (Docket No. PTO-P-2025-0025) Office of Science and Technology Policy (OSTP) Notice of Request for Information (RFI) on Accelerating the American Scientific Enterprise (Docket No. OSTP-TECH-2025-0100) H.R. 791 (Foreign Anti-Digital Piracy Act) S. 2276/H.R. 3269 (Eliminating Thickets to Improve Competition (ETHIC) Act) H.R. 5811 (Restoring Americas Leadership in Innovation Act (RALIA)) H.R. 1833 (Leadership in Critical and Emerging Technologies (CET) Act) H.R. 861/S. 326 (American Music Fairness Act); S. 832/H.R. 1492 (Ensuring Pathways to Innovative Cures (EPIC) Act) S. 832/H.R. 1492 (Ensuring Pathways to Innovative Cures (EPIC) Act) Pharmacy benefits management reform Inflation Reduction Act drug price negotiation H.R. 1 (One Big Beautiful Bill Act) provisions related to proposed government drug price controls known as most favored nation being added to the Medicaid or any program H.R. 1 (One Big Beautiful Bill Act) provisions related to Health Savings Account (HSA) reforms Centers for Medicare & Medicaid Services (CMS) Request for Comments on Medicare Drug Price Negotiation Program Draft Guidance, FR Doc. 2025-0860 Reform and eliminate fraud and abuse of the 340B program for pharmaceutical access by providers of indigent care Allowing the Biden-COVID-era Obamacare premium support credits to expire Centers for Medicare & Medicaid Services (CMS) proposed rules, Global Benchmark forEfficient Drug Pricing (GLOBE) for drugs covered under Medicare Part B (Docket No. CMS-2025-1889-0001) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) for drugs covered under Medicare Part D (Docket No. CMS-2025-1888-0001) Elimination of the Center for Medicare and Medicaid Innovation (CMMI) Approval of reauthorization of Floridas Medicaid hospital-directed payment program (DPP) S. 3315 (Health Care Cybersecurity & Resiliency Act) regarding Sen. Bernie Sanderss amendments to codify Most Favored Nation drug price controls; H.R. 384 (One Agency Act) S. 1040 (Drug Competition Enhancement Act) S. 1096 (Preserve Access to Affordable Generics and Biosimilars Act) S. 527 (Prescription Pricing for the People Act) Seeking ways to lower prescription drug prices by promoting competition without expropriating patent rights; S. 587/H.R. 1301 (Death Tax Repeal Act) Reauthorization and making permanent key Tax Cuts and Jobs Act (TCJA) tax policies, i.e., corporate tax rates, progrowth tax incentive provisions H.R. 2230 (Independent Programmers Tax Incentive Act) H.R. 1 (One Big Beautiful Bill Act), provisions related to permanent death tax relief Proposed 1%-5% wealth or success tax on the value of commercialized U.S. patents H.R. 1340/S. 3332 (More Homes on the Market Act) to adjust the home sale capital gains exclusion for inflation H.R. 7687 (No Tax on Takings Act); Executive Order 14192, Unleashing Prosperity Through Deregulation H. Res. 294 provisions related to proxy voting Government shutdown; Special 301 Report - bolstering U.S. advocacy abroad for respecting intellectual property rights U.S. Trade Representative Request for Comments Regarding Foreign Nations Freeloading on American-Financed Innovation (Docket No. USTR-2025-0011) Employ robust trade policies and pressure tactics to cudgel foreign freeloaders to to stop using drug pricing disparities as a nontariff trade barrier and begin paying their fair share-actual market value-for U.S. medicines U.S. Trade Representative Request for Comments on the Operation of the Agreement between the United States of America, the United Mexican States, and Canada (Docket No. USTR-2025-0004) Urging pursuit in ongoing trade negotiations to ensure Japanese biopharma price controls do not thwart American medical innovation in global markets; H.J. Res. 88, revoking pursuant to the Congressional Review Act California waivers from the Clean Air Act Reform of the definition of the Waters of the United States (WOTUS) under the Clean Water Act; Republican Study Committee FY26 budget proposal; Fannie Mae and Freddie Mac updates permitting mortgage lenders to choose between the current credit score and a new credit score model (Docket No. 2018-27565); H.J. Res. 140 (Congressional Review Act disapproval of Public Land Order (PLO) 7917) issued by the Biden Administration to withdraw more than 225,000 acres of the Superior National Forest from mineral development for 20 years; Suggesting reforms to adjust cost caps and include certain infrastructure under the Blanket Certificate Program
Government Entities
Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), Environmental Protection Agency (EPA), Small Business Administration (SBA), Federal Housing Finance Agency (FHFA), Federal Energy Regulatory Commission (FERC)
IDs
Filing UUID:5ad581d1-e060-4fd9-b402-66991b7a5e37
Registrant ID:401108852
Client ID:61568
2026-04-01
MCDERMOTT+ LLC
PATIENTS FOR AFFORDABLE DRUGS NOW
$30,000
$0
Filing Details
Type: ld2 • Year: 2026 Q1
Specific Issues
Issues related to prescription drug competition and pricing.; Issues related to prescription drug competition and pricing.; Issues related to prescription drug competition, pricing and pharmacy benefit management reforms.
Government Entities
HOUSE OF REPRESENTATIVES, SENATE
IDs
Filing UUID:badf764f-0ac9-4169-ae94-d5dfbbf4e161
Registrant ID:401103287
Client ID:57000
2026-04-01
THE WASHINGTON TAX & PUBLIC POLICY GROUP
ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION
$500,000
$0
Filing Details
Type: ld2 • Year: 2026 Q1
Specific Issues
Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on financial reporting and on the tax base of the U.S. and its Territories. Issues related to the taxation of intellectual property income. Issues related to IRC sections 11, 41 and 174, 55, 56A, and 59, 59A, 163(j), 250, 951A.
Government Entities
HOUSE OF REPRESENTATIVES, SENATE
IDs
Filing UUID:f85b5557-dc26-4b1e-b877-0e174629fd7d
Registrant ID:294930
Client ID:179012
2026-04-01
THE WASHINGTON TAX & PUBLIC POLICY GROUP
REGENERON PHARMACEUTICALS, INC.
$30,000
$0
Filing Details
Type: ld2 • Year: 2026 Q1
Specific Issues
Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, and 174.
IDs
Filing UUID:ef160ad1-7d1a-40ec-b4ae-fa35eacb12ea
Registrant ID:294930
Client ID:64079
2026-03-31
CHECKMATE GOVERNMENT RELATIONS
BLINK HEALTH, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Issues regarding policy changes to pharmacy services and other related issues.
IDs
Filing UUID:a9851ee1-7794-40b4-816c-be51b4560070
Registrant ID:401109039
Client ID:72079
2026-03-30
MICHAEL BEST STRATEGIES LLC
CVS HEALTH
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Issues related to retail pharmacies, insurance, and Medicare/Medicaid.; Issues related to retail pharmacies, insurance, and Medicare/Medicaid.; Issues related to retail pharmacies, insurance, and Medicare/Medicaid.; Issues related to retail pharmacies, insurance, and Medicare/Medicaid.
IDs
Filing UUID:1ca980f1-9d4a-4155-9fbb-f7baf4fba838
Registrant ID:401103565
Client ID:72046
2026-03-30
MILLER STRATEGIES, LLC
ULTRAGENYX PHARMACEUTICAL INC.
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Issues relating to rare disease and patient access.
IDs
Filing UUID:ad803d8d-f727-46df-8a3c-1b5873a9393b
Registrant ID:401104313
Client ID:72066
2026-03-27
PARATEK PHARMACEUTICALS
PARATEK PHARMACEUTICALS
$0
$20,000
Filing Details
Type: ld2 • Year: 2026 Q1
Specific Issues
FY 27 DOD Appropriations FY 27 HHS Appropriations Biodefense Funding
Government Entities
Defense, Dept of (DOD), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
IDs
Filing UUID:93dc04f9-dbae-4b20-9084-d74587196dbf
Registrant ID:401109327
Client ID:64825
2026-03-26
FEROX STRATEGIES
ATRIUM THERAPEUTICS
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
General issues related to rare disease pharmaceuticals.; General issues related to rare disease pharmaceuticals.
IDs
Filing UUID:12538623-5dab-4250-9bc2-137c02e4ee30
Registrant ID:401104769
Client ID:72006
2026-03-24
DENTONS US LLP
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA
$0
$0
Filing Details
Type: ld2 • Year: 2026 Q1
IDs
Filing UUID:1ae18c8c-c4fa-4120-a0f8-d0e47ce27399
Registrant ID:36105
Client ID:53148
2026-03-23
TIBER CREEK GROUP
WE WORK FOR HEALTH
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Issues related to pharmaceutical innovation and pricing.
IDs
Filing UUID:33aa9062-a2b6-4ea3-bad3-80b203e6fa39
Registrant ID:20744
Client ID:212316
2026-03-23
ARNOLD & PORTER KAYE SCHOLER LLP
ESTEVE PHARMACEUTICALS, S.A.
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Issues related to reimbursement and coverage for certain drugs.; Issues related to reimbursement and coverage for certain drugs.
IDs
Filing UUID:f644d85c-f8c0-4f13-878c-2fbf756e33db
Registrant ID:4301
Client ID:71935
2026-03-23
ARNOLD & PORTER KAYE SCHOLER LLP
SUMITOMO PHARMA AMERICA, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.; Issues related to prescription drug pricing, and issues related to small to mid-size pharmaceutical companies.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA (PCCA)
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Issues related to pharmaceutical compounding.
IDs
Filing UUID:861a079c-04eb-4a22-9454-d471767d139a
Registrant ID:320918
Client ID:71856
2026-03-10
ALB SOLUTIONS
VERTEX PHARMACEUTICALS
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Non-opioid pain relief and drug pipeline issues.
Registered Lobbyists (2)
ADAM BUCKALEW ●NEW— Covered Official Positions Continued: Deputy Chief of Staff, U.S. Rep. Markwayne Mullin (R-OK); Communications Director & Legislative Assistant, U.S. Rep. Gregg Harper (R-MS)VERONICA JACKSON ●NEW— Director, Strategic Planning, Office of the Assistant Secretary for Public Affairs, HHS
IDs
Filing UUID:48cd718d-a4e9-41fa-91e7-e86d91b5e7b1
Registrant ID:401105973
Client ID:71687
2026-03-09
MARSHALL & POPP, LLC
GLAXOSMITHKLINE
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Issues related to pharmaceutical manufacturing, drug pricing, trade and tariffs.; Issues related to pharmaceutical manufacturing, drug pricing, trade and tariffs.
Registered Lobbyists (2)
HAZEN MARSHALL ●NEW— Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don NicklesMONICA POPP ●NEW— Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint
IDs
Filing UUID:fb7fed96-f152-4700-bb3d-6cd848a19cac
Registrant ID:401105121
Client ID:71670
2026-03-02
CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS
KYOWA KIRIN, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Issues related to pharmaceuticals.; Issues related to pharmaceuticals.; Issues related to pharmaceuticals.; Issues related to pharmaceuticals.; Issues related to pharmaceuticals.; Issues related to pharmaceuticals.
Registered Lobbyists (2)
MICHAEL CORCORAN ●NEWROBERT BLAIR ●NEW
IDs
Filing UUID:c9cb5ae1-5448-40b7-8cc2-00927a5b951a
Registrant ID:401109009
Client ID:71534
2026-02-27
BALLARD PARTNERS
JUBILANT PHARMA HOLDINGS INC.
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Trade/USMCA renegotiations; Domestic investment
Registered Lobbyists (2)
BRIAN BALLARD ●NEWHUNTER MORGEN ●NEW— Policy Advisor, Office of Policy Planning, U.S. State Dept. (2017); Deputy Director, Office of Trade & Manufacturing Policy, WH (2017-2018); Special Assistant to the President, Office of the Senior Advisor for Policy, WH (2018-2020)
IDs
Filing UUID:5b324631-b9e7-4b4e-bebe-cc2e66d649fb
Registrant ID:401104288
Client ID:71497
2026-02-27
THE CONAFAY GROUP, LLC
BRIGHT PATH LABORATORIES, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Policies that promote domestic pharmaceutical manufacturing.
Registered Lobbyists (2)
BRYAN SHUY ●NEW— Chief of Staff Rep. Harris; Asst. to Rep. Harris, House Cmte on Approps; Dep. Asst. Sec and Chief of Staff HHS/Asst.Secretary for Preparedness and Response (ASPR)JOSH NARROW ●NEW— Intern to Senator Casey
IDs
Filing UUID:dcefddf8-60b1-4e6c-973c-bd5ae32aff3f
Registrant ID:401004840
Client ID:71503
2026-02-24
FARRAGUT PARTNERS LLP
PIERRE FABRE PHARMACEUTICALS, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Issues related to FDA coverage of Tabelecucel
Registered Lobbyists (7)
CONSTANTINE HINGSON ●NEW— Chief of Staff, Senator Dan Coats; Counsel/Legislative Director, Senator Judd Gregg; General Counsel, Senator Elizabeth DoleDYLAN MOORE ●NEW— Intern/Staff Assistant, Speaker John Boehner (OH-8); Legislative Assistant/Legislative Director/Deputy Chief of Staff, Rep. Larry Bucshon (IN-8); Intern, Rep. Mike Turner (OH-10)JEFF MACKINNON ●NEW— LD & LA Rep. Joe Barton (RTexas)JEFFERY MORTIER ●NEW— Prof Staff on E&C Cmte, LA Rep Whitfield and Intern Devin NunesJODY GALE ●NEWSARAH WALTER ●NEW— Former Legislative Director/Chief Counsel, Sen. John BreauxWILLIAM KRIEGER ●NEW
IDs
Filing UUID:f38ac109-e174-49fc-bd38-3869ddf65ba7
Registrant ID:401103938
Client ID:71407
2026-02-24
MARSHALL & POPP, LLC
CURIE BIO OPERATIONS, LLC
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Issues related to the development, testing, and approval of pharmaceutical products.
Registered Lobbyists (2)
HAZEN MARSHALL ●NEW— Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don NicklesMONICA POPP ●NEW— Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint
IDs
Filing UUID:3b1ea2ee-1212-4dd5-8e46-63e0e7796400
Registrant ID:401105121
Client ID:71415
2026-02-24
MARSHALL & POPP, LLC
SUN PHARMACEUTICAL INDUSTRIES, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2026 Q1
Specific Issues
Issues related to pharmaceutical manufacturing. Drug pricing. Trade and tariffs.; Issues related to pharmaceutical manufacturing. Drug pricing. Trade and tariffs.
Registered Lobbyists (2)
HAZEN MARSHALL ●NEW— Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don NicklesMONICA POPP ●NEW— Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint